Lateral Flow Assay (LFA) validation and manufacturing
ID: HCKBG-2025-00447Type: Sources Sought
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFCENTERS FOR DISEASE CONTROL AND PREVENTIONCDC OFFICE OF ACQUISITION SERVICESATLANTA, GA, 30333, USA

NAICS

Analytical Laboratory Instrument Manufacturing (334516)

Original Source

https://sam.gov/opp/05082b6f019b4c09a94d31c66d42b7ca/view
Timeline
    Description

    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking qualified sources for the validation and manufacturing of lateral flow assays (LFA) aimed at diagnosing HIV antiretroviral usage in point-of-care settings. The CDC requires an established medical device company capable of producing 25,000 lateral flow devices, which will be utilized in pre-clinical and clinical studies, with the contractor responsible for adapting the provided technical design to their production pipeline and optimizing test performance. This initiative is part of the broader effort to enhance HIV prevention and treatment strategies, emphasizing the need for rapid and cost-effective assays to monitor drug levels. Interested parties must submit their responses, including organizational details and relevant project experience, to Mark Wirtz at mag8@cdc.gov by January 31, 2025, at 12:00 p.m. EST, as this notice is for market research purposes only and does not constitute a solicitation for proposals.

    Point(s) of Contact
    Mark Wirtz
    mag8@cdc.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Lateral Flow Assay (LFA) validation and manufacturing
    Currently viewing
    Sources Sought
    Similar Opportunities
    Serological Assays for the Detection and Characterization of Influenza Viruses
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is soliciting proposals for a contract focused on serological assays for the detection and characterization of influenza viruses. The primary objectives include performing hemagglutination inhibition assays on human serum samples and developing new serology platforms that are comparable to existing methods. This initiative is crucial for enhancing influenza surveillance and vaccine effectiveness studies, addressing ongoing public health challenges. Interested parties must submit a Letter of Interest by 2:00 PM EST on February 7, 2025, and can contact Jennifer Gartzke at jgartzke@cdc.gov or 404-498-0020 for further information.
    CDC DFWED NARST Sensititre Supplies
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is seeking to award a sole source contract for antimicrobial resistance testing supplies, specifically Sensititre™ broth microdilution testing products, from ThermoFisher Scientific. This procurement is essential for the National Antimicrobial Resistance Monitoring System (NARMS), which has utilized these proprietary materials since 1996 to ensure a standardized approach to monitoring enteric bacteria resistance. The unique nature of these supplies necessitates this sole source approach, as alternatives would require significant investments in new equipment and validation processes, potentially disrupting critical surveillance efforts. Interested parties may respond within 15 days to express their interest, with proposals directed to contract specialist Ashley Williams at dal3@cdc.gov.
    Milliflex Rapid 2.0
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking responses for a Sources Sought Notice regarding the acquisition of the Milliflex Rapid 2.0 microbial detection system. This procurement aims to enhance quality control testing for bioburden contamination in pharmaceutical products, necessitating a system that is compatible with the existing Milliflex Oasis filtration pump currently in use. The initiative is critical for ensuring compliance with quality control standards in pharmaceutical manufacturing, thereby bolstering the FDA's capabilities in evaluating rapid microbial detection methods. Interested vendors must submit their responses by January 30, 2024, at 12:00 PM ET, directed to Contract Specialist Iris Johnson at Iris.Johnson1@fda.hhs.gov and Contracting Officer Maria Finan at Linda.Finan@fda.hhs.gov.
    Pre-Solicitation FY 2025 CDC OS Emerging Public Health Priorities BAA
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is preparing to issue a Fiscal Year 2025 Broad Agency Announcement (BAA) for Applied Research aimed at addressing Emerging Public Health Priorities. This initiative seeks innovative research proposals in various areas, including infectious disease surveillance, wastewater surveillance, and substance use disorder recovery, to enhance public health strategies and responses to emerging threats. The BAA will be open for full and open competition, with a tentative issuance date of December 30, 2024, and a due date for concept papers set for January 30, 2025. Interested contractors must ensure they are registered in the System for Award Management (SAM) to be eligible for award, and further details will be available on SAM.gov.
    Request for Information - Centers for Disease Control and Prevention / National Institute of Occupational Safety and Health / World Trade Center Health Program
    Health And Human Services, Department Of
    The Centers for Disease Control and Prevention (CDC) is issuing a Request for Information (RFI) to gather industry feedback on a draft Performance Work Statement (PWS) related to the operation of a Survivor Clinical Center of Excellence (CCE) for individuals affected by the September 11, 2011 terrorist attacks in the New York metropolitan area. The objective of this procurement is to ensure continued health monitoring and treatment for eligible survivors, with the CDC seeking input on the clarity, completeness, and feasibility of the draft PWS to enhance the potential procurement process. This initiative is critical for providing necessary healthcare services to a vulnerable population, and the feedback received will help refine the evaluation techniques for selecting qualified vendors. Interested parties must submit their feedback to Serina Allingham at xog9@cdc.gov by 12:00 EST on January 31, 2025, and should note that this RFI is for information purposes only and does not constitute a solicitation for proposals.
    Spectrophotometer
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) and its National Institute of Allergy and Infectious Diseases (NIAID), is seeking information on domestically manufactured spectrophotometers through a Sources Sought notice. The objective is to identify products that enhance measurement accuracy and facilitate the early detection of contaminants in laboratory settings, thereby improving data efficiency and reliability. These spectrophotometers will be utilized to determine protein and DNA concentrations, measure optical density, and analyze absorbance spectra, which are critical for various laboratory applications. Interested vendors must submit a capability statement by January 27, 2025, at 5:00 PM EST, detailing their qualifications and confirming that their products are manufactured in the United States. For further inquiries, vendors can contact Jessica Emerson at jessica.emerson@nih.gov or Jesse Weidow at weidowjd@niaid.nih.gov.
    Q515--Molecular analyzers, reagents and maintenance
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is initiating a sole-source acquisition with Roche Diagnostics Corp. for the provision of Microbiology Molecular Diagnostics, which includes specific molecular analyzers, reagents, and maintenance for various FDA-approved real-time PCR tests. The procurement aims to support critical healthcare services by providing qualitative and quantitative testing for conditions such as HIV, COVID-19, HPV, and hepatitis viruses, highlighting the unique capabilities of Roche Diagnostics Corp. as the sole provider for these essential diagnostic tools. Interested parties may express their interest by contacting Contract Officer James E. Boles Jr. at james.boles2@va.gov by 1:00 p.m. local time on January 27, 2025, although this notice does not constitute a request for competitive bids.
    Clinical Studies of Infectious Agents, Vaccines and Antivirals in Adult and Pediatric Human Subjects
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID), is seeking small business contractors to conduct clinical studies focused on infectious agents, vaccines, and antivirals for both adult and pediatric populations. The primary objectives include evaluating the safety, immunogenicity, and efficacy of vaccines against various viruses, including emerging threats like Zika, with a project duration anticipated from August 2026 to August 2033 under a cost-reimbursement IDIQ contract structure. This initiative builds on decades of NIH-led research and aims to advance medical research through strategic partnerships with capable small businesses. Interested parties should submit their capability statements, including prior experience and qualifications, to the primary contact, Uju Obii-Obioha, at uju.obii-obioha@nih.gov, by the specified deadlines.
    Access to Outpatient Longitudinal Drug Utilization Data
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Food and Drug Administration (FDA), is seeking qualified small businesses to provide access to outpatient longitudinal drug utilization data through a Sources Sought notice. The primary objective is to acquire existing, HIPAA-compliant data resources that will enhance drug safety evaluations, support post-market surveillance, and inform regulatory decisions, rather than developing new databases. This initiative is crucial for monitoring medication utilization trends, particularly in areas such as opioid surveillance, and aims to improve public health outcomes through rigorous analyses of drug safety data. Interested firms must submit their responses by January 23, 2025, including their business size status and DUNS number, and can direct inquiries to Telisha Wilson at telisha.wilson@fda.hhs.gov.
    6640--FY 25 Short Term Emergency Contract Molecular Random Access Analyzer
    Veterans Affairs, Department Of
    The Department of Veterans Affairs intends to award a sole-source contract for a Short Term Emergency procurement of a Molecular Random Access Analyzer, specifically the Cepheid GeneXpert Infinity Reagents and Consumables. This procurement is being conducted under FAR 13.5 Simplified Procedures for Certain Commercial Items, emphasizing the need for efficient acquisition of critical laboratory equipment. The selected vendor must demonstrate technical capability to fulfill the requirements, with responses due by January 17, 2025, at 2:00 PM Eastern Time, submitted to Contract Specialist Darrin Alexander at darrin.alexander2@va.gov. The statutory authority for this procurement is U.S.C. § 1901, and the relevant NAICS code is 334516, which pertains to Analytical Laboratory Instrument Manufacturing.